Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Novartis
Queensland Health
Fuji
Johnson and Johnson
AstraZeneca
US Army
Argus Health
QuintilesIMS
Express Scripts
Moodys

Generated: February 25, 2018

DrugPatentWatch Database Preview

Details for Patent: 7,045,620

« Back to Dashboard

Which drugs does patent 7,045,620 protect, and when does it expire?

Patent 7,045,620 protects XIFAXAN and is included in two NDAs.

This patent has eighty-one patent family members in thirty-five countries.
Summary for Patent: 7,045,620
Title:Polymorphous forms of rifaximin, processes for their production and use thereof in medicinal preparations
Abstract:Crystalline polymorphous forms of the rifaximin (INN) antibiotic named rifaximin .alpha. and rifaximin .beta., and a poorly crystalline form named rifaximin .gamma. have been discovered. These forms are useful in the production of medicinal preparations for oral and topical use and can be obtained by means of a crystallization process carried out by hot-dissolving the raw rifaximin in ethyl alcohol and by causing the crystallization of the product by the addition of water at a determinate temperature and for a determinate period of time. The crystallization is followed by drying carried out under controlled conditions until a specific water content is reached in the end product.
Inventor(s): Viscomi; Giuseppe C. (Bologna, IT), Campana; Manuela (Bologna, IT), Braga; Dario (Bologna, IT), Confortini; Donatella (Bologna, IT), Cannata; Vincenzo (Bologna, IT), Severini; Denis (Bologna, IT), Righi; Paolo (Bologna, IT), Rosini; Goffredo (Bologna, IT)
Assignee: Alfa Wassermann, S.p.A. (Alanno, IT)
Application Number:10/728,090
Patent Claim Types:
see list of patent claims
Use; Process;

Drugs Protected by US Patent 7,045,620

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Salix Pharms XIFAXAN rifaximin TABLET;ORAL 021361-001 May 25, 2004 RX Yes Yes ➤ Sign Up ➤ Sign Up Y Y ➤ Sign Up
Salix Pharms XIFAXAN rifaximin TABLET;ORAL 022554-001 Mar 24, 2010 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 7,045,620

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
ItalyMI2003A2144Nov 07, 2003

Non-Orange Book US Patents Family Members for Patent 7,045,620

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,612,199 Polymorphic forms .alpha., .beta., and .gamma. of rifaximin ➤ Sign Up
7,915,275 Use of polymorphic forms of rifaximin for medical preparations ➤ Sign Up
8,404,704 Use of polymorphic forms of rifaximin for medical preparations ➤ Sign Up
7,923,553 Processes for the production of polymorphic forms of rifaximin ➤ Sign Up
8,158,781 Polymorphic forms .alpha., .beta. and .gamma. of rifaximin ➤ Sign Up
8,835,452 Polymorphic forms .alpha., .beta. and .gamma. of rifaximin ➤ Sign Up
8,173,801 Processes for the production of polymorphic forms of rifaximin ➤ Sign Up
8,158,644 Pharmaceutical compositions comprising polymorphic forms .alpha., .beta., and .gamma. of rifaximin ➤ Sign Up
7,902,206 Polymorphic forms .alpha., .beta. and .gamma. of rifaximin ➤ Sign Up
7,906,542 Pharmaceutical compositions comprising polymorphic forms .alpha., .beta., and .gamma. of rifaximin ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 7,045,620

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Ukraine 86384 ➤ Sign Up
Taiwan I285107 ➤ Sign Up
Taiwan 200515913 ➤ Sign Up
Tunisia SN06069 ➤ Sign Up
Tunisia SN04044 ➤ Sign Up
Slovenia 1676848 ➤ Sign Up
Slovenia 1676847 ➤ Sign Up
Slovenia 1557421 ➤ Sign Up
Russian Federation 2270200 ➤ Sign Up
Russian Federation 2004108953 ➤ Sign Up
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

US Department of Justice
AstraZeneca
Daiichi Sankyo
Julphar
Accenture
Cipla
Harvard Business School
Queensland Health
Fuji

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot